UROTHELIAL CARCINOMA RECURRENT
Clinical trials for UROTHELIAL CARCINOMA RECURRENT explained in plain language.
Never miss a new study
Get alerted when new UROTHELIAL CARCINOMA RECURRENT trials appear
Sign up with your email to follow new studies for UROTHELIAL CARCINOMA RECURRENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug duo targets hard-to-treat bladder cancer in phase 2 trial
Disease control Recruiting nowThis study tests a new drug (trastuzumab rezetecan) alone or with an immunotherapy (adebrelimab) in people with advanced bladder cancer that has spread and shows HER2 protein. About 96 adults with HER2-positive urothelial carcinoma will receive the treatment to see if tumors shri…
Matched conditions: UROTHELIAL CARCINOMA RECURRENT
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 26, 2026 07:22 UTC
-
New bladder cancer treatment aims to keep cancer from coming back
Disease control Recruiting nowThis study tests a new version of BCG treatment (VERITY-BCG) for people with intermediate or high-risk non-muscle invasive bladder cancer who have not received BCG before. The goal is to see if the new treatment is as good as the standard BCG at preventing the cancer from returni…
Matched conditions: UROTHELIAL CARCINOMA RECURRENT
Phase: PHASE3 • Sponsor: Verity Pharmaceuticals Inc. • Aim: Disease control
Last updated May 18, 2026 12:02 UTC